Who are Bilastine Ophthalmic Solution 0.6%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Azelastine - intranasal application, Antihistamine Cetirizine Hydrochloride, Ciclesonide & Levocetirizine, Atarax (Hydroxyzine), diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan, Diphenhydramine 5%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bilastine-ophthalmic-solution-0-6.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Bilastine Ophthalmic Solution 0.6% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bilastine Ophthalmic Solution 0.6% (Bilastine Ophthalmic Solution 0.6%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective H1-receptor antagonist (antihistamine). Area: Ophthalmology / Allergy.

phase 3 Selective H1-receptor antagonist (antihistamine) H1 histamine receptor Ophthalmology / Allergy Small molecule Live · refreshed every 30 min

Target snapshot

Bilastine Ophthalmic Solution 0.6% (Bilastine Ophthalmic Solution 0.6%) — Faes Farma, S.A.. Bilastine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the eye.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Bilastine Ophthalmic Solution 0.6% TARGET	Bilastine Ophthalmic Solution 0.6%	Faes Farma, S.A.	phase 3	Selective H1-receptor antagonist (antihistamine)	H1 histamine receptor
Azelastine - intranasal application	Azelastine - intranasal application	Association Asthma, Bulgaria	marketed	Selective H1-receptor antagonist (intranasal antihistamine)	H1 histamine receptor
Antihistamine Cetirizine Hydrochloride	Antihistamine Cetirizine Hydrochloride	Goldman, Butterwick, Fitzpatrick and Groff	marketed	H1-receptor antagonist (second-generation antihistamine)	H1 histamine receptor
Ciclesonide & Levocetirizine	Ciclesonide & Levocetirizine	Handok Inc.	marketed	Inhaled corticosteroid + selective H1-receptor antagonist combination	Glucocorticoid receptor (ciclesonide); H1 histamine receptor (levocetirizine)
Atarax (Hydroxyzine)	Atarax (Hydroxyzine)	University Hospital, Toulouse	marketed	First-generation H1 antihistamine	H1 histamine receptor
diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan	diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan	Montefiore Medical Center	marketed	Combination cold/cough/allergy remedy	H1 histamine receptor (diphenhydramine); alpha-1 adrenergic receptor (phenylephrine); NMDA receptor and sigma-1 receptor (dextromethorphan)
Diphenhydramine 5%	Diphenhydramine 5%	Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology	marketed	H1 receptor antagonist (first-generation antihistamine)	H1 histamine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective H1-receptor antagonist (antihistamine) class)

Faes Farma, S.A. · 2 drugs in this class
ORA, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bilastine Ophthalmic Solution 0.6% — Competitive Intelligence Brief. https://druglandscape.com/ci/bilastine-ophthalmic-solution-0-6. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab